Q4 2023: Net sales of $509 million (+2% actual rates, +1% constant exchange rates, CER); diluted EPS of $0.42 and adjusted diluted EPS of $0.55 ($0.55 CER vs. $0.53 CER outlook) // FY 2023: Achieved outlook for at least $1.97 billion CER sales and at least $2.07 CER adj. EPS, +8% CER sales growth in non-COVID portfolio and 27% adj. operating income margin // 2024 outlook for at least $2.0 billion CER net sales; adj. diluted EPS of at least $2.10 CER, reflects adj. operating income margin gains but significant non-operating income pressure Q4 2023: Net sales of $509 million (+2% actual rates, +1% constant exchange rates, CER); diluted EPS of $0.42 and adjusted diluted EPS of $0.55 ($0.55 CER vs. $0.53 CER outlook) // FY 2023: Achieved outlook for at least $1.97 billion CER sales and at least $2.07 CER adj. EPS, +8% CER sales growth in non-COVID portfolio and 27% adj. operating income margin // 2024 outlook for at least $2.0 billion CER net sales; adj. diluted EPS of at least $2.10 CER, reflects adj. operating income margin gains but significant non-operating income pressure

Continue reading here:
QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability